MedTrace Logo

Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury

NCT05585255 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2024-03-25

No results posted yet for this study

Summary

The study is a two-center prospective cohort clinical trial. The primary purpose of this trial is to identify the pattern of DKK2 serum levels in ischemic stroke patients after revascularization therapy and determine the correlation between serum DKK2 levels and prognosis.

Conditions

  • Ischemic Stroke, Acute
  • Ischemia-reperfusion Injury
  • Cerebral Edema

Interventions

DIAGNOSTIC_TEST

enzyme-linked immunosorbent assay(ELISA)

After allowing to stand at room temperature for 2h, blood samples are centrifuged at 4 ℃ for 15 min (12000 rpm) to collect the supernatant. Then, the levels of DKK2, IL-6, IL-1β, TNF-α, and IL-10 in the supernatants are tested by ELISA detection.

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Zhu Shi, PHD · Dongguan Hospital of Southern Medical University

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05585255 on ClinicalTrials.gov